The dependence of the prostate on hormonal stimulation for its growth and development has been known for a long time, but it was not until 1941 that Huggins and Hodges found that androgen injection in patients with prostatic carcinoma had a harmful effect and that oestrogen injection or castration were beneficial.' Almost 75% of patients with prostatic carcinoma present with inoperable metastatic tumours,2 and treatment with oestrogen or castration produced evident improvement in 60-80% of these patients.24 Some patients, however, subsequently relapse and prove insensitive to further hormonal treatment,5 leaving only the options of cytotoxic drugs or radiotherapy for the further management of the tumour.
Androgen receptor concentrations have begun to be assayed in prostatic carcinoma to determine which tumours (with high androgen receptor concentrations) are most likely to respond to hormonal treatment. Several reports have shown a correlation between androgen receptor concentration and a favourable clinical response to endocrine treatment,64 but this is not a universal finding.9"' The importance of previous studies is difficult to assess, however, because of the variety of assay methods used and questionable tissue sampling techniques with no histological verification of the presence of tumour in the assayed sample.
Most androgen receptor assays are performed on homogenised prostatic tissue samples, but it is quesAccepted for publication 4 To investigate the specificity of binding of 323 mibolerone to cytosolic androgen receptor pooled cytosols were incubated with 5 x 10-9M [3H]-mibolerone either alone or in the presence of a 100-fold molar excess of mibolerone, testosterone, progesterone, ORG-2058, diethylstilboestrol or hydrocortisone (in the absence of the 1000-fold molar excess of ORG-2058 routinely used in the assay to block the binding of mibolerone to progesterone receptor).
After incubation the receptor-bound [3H]-mibolerone was assayed as below.
Supernatant samples (100 p1) from the incubation of cryostat sections with [3H]-mibolerone were subjected to isoelectric focusing in a thin layer polyacrylamide gel (245 x 110 x 2 mm; 2-4% (weight/volume) ampholine, pH 3 5-9 5; (Pharmacia Ltd) under conditions similar to those used by Gustafsson et al. 27 At the end of the focusing period gel slices (5 mm) were incubated in 4 ml of HP/b scintillant (Beckman) at 50°C for one hour, with gentle agitation.
The radioactivity of each phial was measured by liquid scintillation counting, with quench monitoring by H number (external standard Compton edge monitoring with '37Caesium), using a Beckman LS1801 automated liquid scintillation spectrometer. A histogram of radioactivity against gel slice number was plotted for each sample and the cumulative height of the points in the single peak, at pH 6-6, was measured above the diagrammatic baseline. 29 The cellularity of the assayed cryostat sections with regard to their epithelial or neoplastic cell content was estimated by point counting203" on the adjacent sections stained with haematoxylin and eosin for light microscopy. The fraction of points coincident with epithelial or tumour cells was recorded for each field until the entire section had been covered. The mean value was calculated and the result expressed as a percentage estimate of the sectional area occupied by epithelium or tumour.
"Crude" androgen receptor concentrations were "corrected" for epithelial cellularity using the formula: "corrected" androgen receptor = "crude" androgen receptor x 100 cellularity (%) 
Results

HISTOLOGY
Benign prostatic hyperplasia was confirmed on the cryostat and paraffin wax sections from nine retropubic and nine TURP specimens. Prostatic adenocarcinoma was present in only six of the nine cryostat sections of tissue selected for androgen receptor assay from the patients with prostatic cancer, but carcinoma was present in paraffin wax sections from all nine of these prostates.
ANDROGEN RECEPTOR CHARACTERISTICS
Two peaks of androgenic binding of (3HJ-mibolerone to prostatic cytosol were detected after isoelectric focusing (fig 1) . The peak at pH 6-6 represents high affinity, low capacity androgen receptor binding, as In the six RPP samples containing prostatic adenocarcinoma the mean "crude" androgen receptor concentration was 151 (% range 1 4-867) fmol/mg cytosol protein. Androgen receptor concentration "corrected" for epithelial cellularity was 166-6, range 3 5-912 7 fmol/mg cytosol protein. The epithelial cellularity within prostatic adenocarcinomas was variable both within and between individual tumours (fig 5) . "Correction" for epithelial cellularity did not change the ranking of androgen receptor concentration results in this small number of samples, but one tumour changed from being "androgen receptor negative" (androgen receptor of < 10 fmol/mg cytosol protein) to "androgen receptor positive" as a result of this "correction" (fig 6) .
The mean protein concentration in prostatic cytosol preparations was 117-9 pg/100 p1, range 40-8-183-0 pg/100 p1).
Discussion
The main advantage of this cryostat section androgen receptor microassay is that it incorporates both a biochemical assay and histological assessment of the assayed tissue on near-facsimile sections; in conventional biochemical assays correlative histological examination, if any, is performed on tissue some distance from the assayed sample. This was reflected in the study of specimens with prostatic adenocarcinoma; only six of the nine samples judged to contain adenocarcinoma on the basis of macroscopic examination ofthe tissue alone had carcinoma present in the cryostat sections. Thus correct tumour sampling, tissue heterogeneity, and presence of diathermy or other artefact can be assessed using this method.
Our assay uses the synthetic androgenic radioligand "Crude" androgen receptor concentrations were significantly lower in TURP than in RPP samples of benign prostatic hyperplasia, a difference which disappeared when the androgen receptor concentration was "corrected" for epithelial cellularity. This new observation may reflect lower androgen receptor concentrations in TURP samples caused by heat inactivation of androgen receptors during electroresection, as shown by Gustafsson et al with progesterone receptors in experimental electroresection of prostatic tissue.6 Tissue sampling may be a factor causing these differences as RPP samples were often from the periphery of the gland, whereas TURP samples were from periurethral tissue. The central and peripheral zones of the prostate have very different structures, development, and hormone sensitivities37; the central zone responds more to maternal oestrogen stimulation in the uterus38 and to oestrogen in the mature gland39 than the peripheral zone, and prepubertal growth is also greater in this zone.' Thus the central zone, sampled during TURP, might be expected to contain lower androgen receptor concentrations than the peripheral zone. There is also more periglandular stroma in the central zone than in the periphery of the gland`; this proportionally reduces the epithelial content of the central zone, thereby increasing the "corrected" androgen receptor concentrations to concentrations similar to those of the peripheral gland.
Benign prostatic hyperplasia affects the periurethral and central zone of the prostate; prostatic carcinoma develops in the androgen sensitive peripheral zone of the gland.37 In benign prostatic hyperplasia TURP samples and "peripheral" samples of even larger RPP specimens consist predominantly of hypertrophied central zone prostatic tissue, and should, in theory, have similar hormonal sensitivity and hormone receptor concentrations.
In prostatic carcinoma TURP may remove normal or hyperplastic central zone tissue and peripheral zone tissue from which the carcinoma develops, but it is impossible to differentiate between these zones histologically in cryostat sections.
We believe that our observations on TURP and RPP samples in benign prostatic hyperplasia result from heat inactivation of androgen receptors during electroresection (TURP), and we recommend that TURP specimens should not be used for the evaluation of androgen receptor concentrations in prostatic tissue. Upward "correction" of androgen receptor concentrations in TURP samples are probably an artefact resulting from zonal differences in the epithelial:stromal ratio in the prostate.
Our six confirmed prostatic adenocarcinomas showed a wide range of androgen receptor concentrations, probably resulting from a combination of real differences in androgen receptors between tumours and heat inactivation of androgen receptors during TURP. "Correction" for the variable epithelial cellularity did not affect the ranking of tumours with respect to androgen receptor concentrations, although one tumour became androgen receptor "positive". The validity of "correcting" tumour androgen receptor concentrations for epithelial cellularity is questionable, however, as it depends on the unlikely assumption that androgen receptors are present in epithelial but not stromal cells. If this asslimption is correct, or if androgen receptors are more concentrated in epithelial cells than in the stroma, then "corrected" androgen receptor concentrations may be more valuable than "crude" androgen receptor concentrations. Monoclonal antibodies to androgen receptors for immunolocalisation of androgen receptors in epithelial or stromal cells will be valuable in this context. Many more tumours must be assayed by this method, and the correlation between "corrected" androgen receptor values and response to endocrine manipulation in patients with prostatic adenocarcinoma must be evaluated before the validity of these "corrected" results and their clinical usefulness can be fully assessed. This type of assay may be of greater predictive value in determining the likely response to endocrine treatment than existing conventional biochemical androgen receptor assays. 
